



MAY 5-6, 2024 ROME
LE MERIDIEN VISCONTI

3rd INTERNATIONAL SUMMIT ON LUNG CANCER

UNDER THE AUSPICES OF

SCIENTIFIC BOARD



FEDERICO CAPPUZZO

Oncology Department Director
Istituto Nazionale Tumori "Regina Elena"
Rome, Italy



ENRIQUETA FELIP FONT

Head of the Lung Cancer Unit, Oncology Department
Vall d'Hebron University Hospital
Barcelona, Spain



LORENZA LANDI

Oncology Department
Istituto Nazionale Tumori "Regina Elena"
Rome, Italy



SILVIA NOVELLO

Professor of Medical Oncology, Oncology Department
AOU San Luigi, University of Turin
Turin, Italy

SCIENTIFIC SECRETARIAT



GABRIELE MINUTI

Physician Oncology Department
Istituto Nazionale Tumori "Regina Elena"
Rome, Italy



PAOLO BIRONZO

Assistant Professor, Oncology Department
AOU San Luigi, University of Turin
Turin, Italy

09.00 **Message of IFO Scientific Director** Gennaro Ciliberto

THE TWO SIDES OF THE COIN

Presenter Federico Cappuzzo

09.10 Lecture: **Preventing lung cancer: hope or reality?** Ugo Pastorino

09.40 Lecture: **Early palliative care in lung cancer** David Hui

MANAGEMENT OF RESECTABLE ONCOGENE-ADDICTED NSCLC

Expert Panel: Emilio Bria, Lucio Crinò, Marina Chiara Garassino, Pilar Garrido Lopez, Yi Long Wu, Umberto Malapelle, Giulio Metro, Jarushka Naidoo, Nicola Normanno, Giuseppe Perrone

10.10 **Anti-EGFR agents in the adjuvant setting** Yi Long Wu

10.20 **Anti-ALK agents as adjuvant therapy** Marina Chiara Garassino

10.30 **Neoadjuvant or adjuvant target therapy in resectable oncogene-addicted NSCLC?** Jarushka Naidoo

10.40 **MRD in early stage oncogene-addicted NSCLC** Nicola Normanno

10.50 **Expert Panel discussion**

MANAGEMENT OF RESECTABLE NON ONCOGENE-ADDICTED NSCLC

Expert Panel: Rosario Garcia Campelo, Tina Cascone, Francesco Facciolo, Patric Forde, Dolores Isla, Tony Mok, Mariano Provencio, Erino Angelo Rendina, Jonathan Spicer, Piergiorgio Solli

11.30 **Surgery at the time of immunotherapy for early stage disease** Jonathan Spicer

11.40 **Adjuvant immunotherapy is the best option for resected NSCLC** Dolores Isla

11.50 **Neoadjuvant immunotherapy is the best option for resected NSCLC** Mariano Provencio

12.00 **Perspectives for patients not obtaining complete pathological response** Tony Mok

12.10 **Adjuvant or neoadjuvant immunotherapy?** Tina Cascone

12.20 **Expert Panel discussion**

13.00>14.00 Lunch

INTEGRATED THERAPIES FOR STAGE III NSCLC

Expert Panel: Fabrice Barlesi, Federica Biello, Mariana Brandão, Rita Chiari, Anne-Marie Dingemans, Domenico Galetta, Cecile Le Pechoux, Gabriele Minuti, Isabelle Schmitt-Opitz

14.00 **N2 disease: Who is resectable?** Mariana Brandão

14.10 **Radiotherapy for N2 resected NSCLC** Cecile Le Pechoux

14.20 **Maintenance immunotherapy in stage III unresectable NSCLC** Anne-Marie Dingemans

14.30 **New drugs as maintenance therapy after chemoradiotherapy in stage III** Fabrice Barlesi

14.40 **Is neoadjuvant chemoimmunotherapy changing the algorithm of therapy in unresectable disease?**

Isabelle Schmitt-Opitz

14.50 **Expert Panel discussion**

RELEVANCE OF STAGING

Presenter Silvia Novello

15.30 Lecture **The forgotten mediastinal staging** Rocco Trisolini

16.00 Lecture **Neoadjuvant and adjuvant therapies: Are we saving lives?** Giorgio V. Scagliotti

SMALL CELL LUNG CANCER AND MESOTHELIOMA

Expert Panel: Joachim Aerts, Andrea Ardizzoni, Paolo Bironzo, Fabiana Letizia Cecere, Alessandra Curioni-Fontecedro, Federica Grosso, Luis Paz-Ares Rodríguez, Charles Rudin

16.30 **Current options in advanced SCLC** Charles Rudin

16.40 **Current and future options for relapsed SCLC** Luis Paz-Ares Rodríguez

16.50 **Immunotherapy for patients with pleural mesothelioma** Joachim Aerts

17.00 **Expert Panel discussion**

17.40 **Conclusion first day**



IMMUNOTHERAPY FOR ADVANCED NSCLC

Expert Panel: Federico Cappuzzo, Rafal Dziadziuszko, Siow Ming Lee, Giulia Pasello, Francesco Passiglia, Solange Peters, Jordi Remon Masip, Biagio Ricciuti, Christian Rolfo, Ross Soo, Rolf Stahel, Marcello Tiseo

- 09.00 **Long term results with checkpoint inhibitors** Rolf Stahel
- 09.10 **Selecting patients for CTLA4 therapy** Rafal Dziadziuszko
- 09.20 **New checkpoint inhibitors** Solange Peters
- 09.30 **Optimal duration of immunotherapy** Giulia Pasello
- 09.40 **Immunotherapy for oncogene-addicted NSCLC-Any role?** Francesco Passiglia
- 09.50 **Biomarkers for immunotherapy** Biagio Ricciuti
- 10.00 **ctDNA in immunotherapy** Christian Rolfo
- 10.10 **Next generation immunotherapies** Ross Soo
- 10.20 **Cardiotoxicity and immunotherapy** Jordi Remon Masip
- 10.30 **Expert Panel discussion**

ANTIBODY DRUG CONJUGATES

Expert Panel: Hossein Borghaei, Romano Danesi, Marzia Del Re, Enriqueta Felip Font, Francesco Grossi, Lizza Hendriks, Fred Hirsch, Natasha Leighl, Stephen Liu, Noemi Reguart, Delvys Rodriguez-Abreu

- 11.10 **Pharmacology of ADC Classes** Marzia del Re
- 11.20 **Current ADC Development in NSCLC** Hossein Borghaei

- 11.30 **ADC in pretreated NSCLC** Noemi Reguart
- 11.40 **ADC in combination with immunotherapy** Stephen Liu
- 11.50 **Potential role of ADC in early stages** Enriqueta Felip Font
- 12.00 **Management of ADC Associated Toxicities** Natasha Leighl
- 12.10 **ADC as target therapy** Fred Hirsch
- 12.20 **Expert Panel discussion**

13.00>14.00 Lunch

ADAPTIVE MECHANISMS OF DRUG RESISTANCE

Expert Panel: Chiara Ambrogio, Jair Bar, Ruggero De Maria, Paola Nisticò, Keunchil Park, Dario Sangiolo

- 14.00 **Mechanisms of resistance to target therapies** Chiara Ambrogio
- 14.10 **Tumour Immune Microenvironment and Immunotherapy Resistance** Dario Sangiolo
- 14.20 **Potential mechanisms of resistance to ADC** Jair Bar
- 14.30 **Expert Panel discussion**

OLD AND NEW TARGET THERAPIES FOR NSCLC

Expert Panel: Benjamin Besse, Trever Bivona, Roberto Ferrara, Oliver Gautschi, Pasi A. Jänne, Lorenza Landi, Jessica Lin, Margarita Majem, Laura Mezquita, Silvia Novello, David Planchard, Rafael Rosell, Ferdinandos Skoulidis, Egbert F. Smit

- 15.10 **How to select EGFR mutated patients for EGFR+CT combo** Pasi A. Jänne
- 15.20 **Options for Osimertinib-resistant NSCLC** Trever Bivona
- 15.30 **Drugging exon 20 mutations** Laura Mezquita
- 15.40 **New drugs for HER2 deregulated NSCLC** Egbert F. Smit
- 15.50 **Options for ALK+ NSCLC** Jessica Lin
- 16.00 **Therapies for ROS1+ NSCLC** Lorenza Landi
- 16.10 **Options for MET exon 14 mutated patients** Oliver Gautschi
- 16.20 **KRAS inhibitors for lung cancer** Rafael Rosell
- 16.30 **Options for BRAF mutant patients** David Planchard
- 16.40 **RET inhibitors in lung cancer** Benjamin Besse
- 16.50 **Options for NTRK rearranged tumors** Roberto Ferrara
- 17.00 **Expert Panel discussion**
- 17.30 **Closing remarks** Federico Cappuzzo

FACULTY

Joachim Aerts
Rotterdam - NL

Chiara Ambrogio
Turin - IT

Andrea Ardizzoni
Bologna - IT

Jair Bar
Tel Aviv - IL

Fabrice Barlesi
Paris- F

Benjamin Besse
Paris- F

Federica Biello
Novara - IT

Paolo Bironzo
Turin - IT

Trever Bivona
San Francisco - US

Hossein Borghaei
Philadelphia - US

Mariana Brandão
Brussels - BE

Emilio Bria
Rome - IT

Federico Cappuzzo
Rome - IT

Tina Cascone
Houston - US

Fabiana Letizia Cecere
Rome - IT

Rita Chiari
Pesaro Urbino - IT

Gennaro Ciliberto
Rome - IT

Lucio Crinò
Meldola/Forlì - IT

Alessandra Curioni-Fontecedro
Freiburg - CH

Romano Danesi
Milan - IT

Ruggero De Maria
Rome - IT

Marzia Del Re
Pisa - IT

Anne-Marie Dingemans
Maastricht - NL

Rafal Dziadziuszko
Danzica - PL

Francesco Facciolo
Rome - IT

Enriqueta Felip Font
Barcelona - E

Roberto Ferrara
Milan - IT

Patrick Forde
Baltimora - US

Domenico Galetta
Bari - IT

Marina Chiara Garassino
Chicago - US/Milan - IT

Rosario Garcia Campelo
Coruña - E

Pilar Garrido Lopez
Madrid - E

Oliver Gautschi
Lucerne - CH

Francesco Grossi
Varese - IT

Federica Grosso
Alessandria - IT

Lizza Hendriks
Maastricht - NL

Fred Hirsch
New York - US

David Hui
Houston - US

Dolores Isla
Zaragoza - E

Pasi A. Jänne
Boston - US

Lorenza Landi
Rome - IT

Cecile Le Pechoux
Paris- F

Siow Ming Lee
London - UK

Natasha Leighl
Toronto - CDN

Jessica Lin
Boston - US

Stephen Liu
Georgetown - US

Margarita Majem
Barcelona - E

Umberto Malapelle
Naples - IT

Giulio Metro
Perugia - IT

Laura Mezquita
Barcelona - E

Gabriele Minuti
Rome - IT

Tony Mok
Hong Kong SAR

Jarushka Naidoo
Dublin - IRL

Paola Nisticò
Rome - IT

Nicola Normanno
Naples - IT

Silvia Novello
Turin - IT

Keunchil Park
Houston - US

Giulia Pasetto
Padua - IT

Francesco Passiglia
Turin - IT

Ugo Pastorino
Milan - IT

Luis Paz-Ares Rodríguez
Madrid - E

Giuseppe Perrone
Rome - IT

Solange Peters
Lausanne - CH

David Planchard
Villejuif - F

Mariano Provencio
Madrid - E

Noemi Reguart
Barcelona - E

Jordi Remon Masip
Paris - F

Erino Angelo Rendina
Rome - IT

Biagio Ricciuti
Boston - US

Delvys Rodriguez-Abreu
Gran Canaria - E

Christian Rolfo
New York - US

Rafael Rosell
Barcelona - E

Charles Rudin
New York - US

Dario Sangiolo
Turin - IT

Giorgio Vittorio Scagliotti
Turin - IT

Isabelle Schmitt-Opitz
Zurich - CH

Ferdinandos Skoulidis
Houston - US

Egbert F. Smit
Leida - NL

Solange Peters
Lucerne - CH

Piergiorgio Solli
Bologna - IT

Ross Soo
Singapore - MY

Jonathan Spicer
Montreal Trudeau - CDN

Rolf Stahel
Zurich - CH

Marcello Tiseo
Parma - IT

Rocco Trisolini
Rome - IT

Yi-Long Wu
Guangdong - RC

GENERAL INFORMATION

The event will be entirely recorded.

Meeting recording will be available after the Summit's end

VENUE

Hotel Le Meridien Visconti Rome Via Federico Cesi, 37 - 00193 Roma

REGISTRATION

This event will be held in presence and in live streaming.

ONLINE (NO CME)

If you are not interested in CME credits and want to join online you can register at this link: [First Day](#) | [Second Day](#)

CME INFORMATION

The event will be accredited by the Italian Ministry of Health. **The CME Provider is MI&T srl (ID 1509).** This CME event will be held in presence (CME - RES) and in live streaming (CME - FAD). Credits will be available in both ways.

Registration is free of charge. Please complete the process to register at our site www.mitcongressi.it

PARTICIPATION ONLINE (CME - FAD) 21 CME for Italian participants only. [Click here to register](#)

PARTICIPATION ON-SITE (CME - RES) 14 CME for Italian participants only. [Click here to register](#)

The scientific sessions will be accredited for the following professionals Medical specialties: **Pharmacy, Biology, Biomedical Technician, Medical Radiology Technician, Medical Physic, Surgeon** (Allergy and Immunology - Anatomic and Clinical Pathology - Anesthesiology - General Surgery - Thoracic Surgery - Palliative Medicine - Hospital Clinical management - Pharmacology and Medical Toxicology - Genetics - Pulmonary Disease - Internal Medicine - Nuclear Medicine - Oncology - Pathology - Radiation Oncology - Diagnostic Radiology), **Cardiocirculatory and Cardiovascular Perfusion Technitian, Nurse**

CME INSTRUCTIONS

The CME Questionnaire and Certificate of Participation will be available online by accessing our platform in the "My courses" section of your reserved area. To qualify for CME Credits, participants are required to attend at least 90% of the accredited sessions and the detection of the presence and the compilation of the satisfaction questionnaire of the event will also be mandatory. **The deadline for the completion of the CME assessment questionnaire and the course approval questionnaire is set within 72 hours from the end of the course. You will need a score of 75% or higher on the learning assessment questionnaire.**

Question about the upcoming conference? Email: cecilia.michielin@mitcongressi.it

ORGANIZATIONAL SUPPORT

Anna Maria Edilisca

PROVIDER AND LOGISTIC SECRETARIAT



MI&T srl Centro Direzionale Bolomna Via Guelfa, 5 - 40138 Bologna
info@mitcongressi.it - www.mitcongressi.it

UNRESTRICTED GRANT BY

GOLD



SILVER

abbvie

AstraZeneca

Bristol Myers Squibb™

NOVARTIS

Pfizer
Oncology

REGENERON®

Roche

BRONZE

Alentis
THERAPEUTICS

AMGEN



BeiGene

Boehringer
Ingelheim



Daiichi-Sankyo



Johnson & Johnson

Lilly

MERCK

OSE IMMUNO
THERAPEUTICS

Pharma
Mar



ThermoFisher
SCIENTIFIC